Background

Remedium Biotechnologies is a regenerative medicine biotech company focused on addressing age-related diseases and significant unmet clinical needs. A key problem in this field is the inefficiency of current treatments for conditions like Osteoarthritis (OA), Type 2 Diabetes (T2D), and obesity. For instance, OA treatments are limited by the pharmacokinetics of the joints, requiring frequent FGF18 protein injections, while protein-based treatments for T2D and obesity suffer from pharmacokinetic sawtoothing, leading to safety and efficacy concerns. Gene therapy offers a potential solution but is hindered by high costs, inflexibility in dosage adjustments post-administration, and the inability to discontinue treatment if needed.

Aims and Progress to Date

Remedium aims to revolutionize therapeutic protein delivery with its proprietary Prometheus™ gene delivery platform. This technology is designed for highly localized, durable expression of therapeutic genes, offering adjustable dosing capabilities and avoiding the limitations of current gene therapy methods. Remedium's lead candidate, RMD1101, is a pioneering regenerative treatment for OA, delivering the FGF18 transgene to arthritic joints. This treatment has demonstrated significant efficacy in preclinical models, showing dose-dependent increases in cartilage thickness and improved safety profiles. Additionally, their RMD1202 treatment for obesity and T2D has shown promising results in preclinical models, matching the efficacy of daily incretin injections while potentially reducing side effects due to minimized pharmacokinetic spikes.

Timeline

Remedium is progressing towards licensing its Prometheus™ platform to major pharmaceutical and biotech companies, anticipated in the first half of 2024. Additionally, two IND submissions are planned for Q1 and Q4 of 2025 on RMD compounds. Their platform is also being evaluated for a range of other applications, including treatments for diabetes, rheumatoid arthritis, atopic dermatitis, enzyme replacement therapies, and longevity enhancement.
Given the significant market opportunities in these areas, and the platform's potential to improve efficacy, reduce costs, and enhance patient tolerability, Remedium is well-positioned for substantial growth and impact in the regenerative medicine and biotech sectors in the coming years.

Series A Round
Required Funding: $15M
Duration: Ongoing

VitaDAO Board Evaluation Writeup

The Prometheus™ platform offers a cost-effective, adjustable gene therapy delivery for a range of treatments. Key products include RMD1101, a first-in-class regenerative therapy for Osteoarthritis leveraging the clinically validated FGF18 mechanism, and RMD1202, a novel single injection treatment for Type 2 Diabetes, poised to overcome the limitations of existing therapies. Backed by a seasoned leadership team with a history of successful therapy development and commercialization, Remedium is well-positioned in the biotech field. However, the company faces typical preclinical biotech risks including manufacturing, regulatory challenges, and market-driven financial uncertainties. To mitigate these risks, Remedium has employed strategies like utilizing multiple contract development and manufacturing organizations, extensive preclinical testing, leveraging clinically validated technological elements, a tiered intellectual property strategy, and efficient fund utilization through academic collaborations and strategic staffing.